Evaluation of the DLL3-targeting Antibody–Drug Conjugate Rovalpituzumab Tesirine in Preclinical Models of Neuroblastoma

Neuroblastomas have neuroendocrine features and often show similar gene expression patterns to small cell lung cancer including high expression of delta-like ligand 3 (DLL3). Here we determine the efficacy of rovalpituzumab tesirine (Rova-T), an antibody–drug conjugated (ADC) with a pyrrolobenzodiaz...

Descripción completa

Detalles Bibliográficos
Autores principales: Krytska, Kateryna, Casey, Colleen E., Pogoriler, Jennifer, Martinez, Daniel, Rathi, Komal S., Farrel, Alvin, Berko, Esther R., Tsang, Matthew, Sano, Renata R., Kendsersky, Nathan, Erickson, Stephen W., Teicher, Beverly A., Isse, Kumiko, Saunders, Laura, Smith, Malcolm A., Maris, John M., Mossé, Yael P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9648412/
https://www.ncbi.nlm.nih.gov/pubmed/36381237
http://dx.doi.org/10.1158/2767-9764.CRC-22-0137

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9648412/
https://www.ncbi.nlm.nih.gov/pubmed/36381237
http://dx.doi.org/10.1158/2767-9764.CRC-22-0137

Ejemplares similares